Biocon's Breast Cancer Biosimilar Gets USFDA Panel Nod, Shares Surge

New Delhi: Drug majors Mylan and Biocon today said the US health regulator's Oncologic Drugs Advisory Committee (ODAC) has recommended approval for their proposed biosimilar trastuzumab, indicated for breast cancer treatment. In a regulatory filing, Biocon said the committee voted 16-0 in support of eligible indications of the reference product. "This vote marks first proposed biosimilar Trastuzumab to be recommended by the committ...